NO20051159L - Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein - Google Patents

Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein

Info

Publication number
NO20051159L
NO20051159L NO20051159A NO20051159A NO20051159L NO 20051159 L NO20051159 L NO 20051159L NO 20051159 A NO20051159 A NO 20051159A NO 20051159 A NO20051159 A NO 20051159A NO 20051159 L NO20051159 L NO 20051159L
Authority
NO
Norway
Prior art keywords
preparations
methods
diseases
treatment
protein aggregation
Prior art date
Application number
NO20051159A
Other languages
English (en)
Norwegian (no)
Inventor
Eric B Kmiec
Hetal Parekh-Olmedo
Original Assignee
Univ Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Delaware filed Critical Univ Delaware
Publication of NO20051159L publication Critical patent/NO20051159L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
NO20051159A 2002-08-07 2005-03-04 Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein NO20051159L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40219802P 2002-08-07 2002-08-07
PCT/US2003/024868 WO2004014306A2 (en) 2002-08-07 2003-08-07 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation

Publications (1)

Publication Number Publication Date
NO20051159L true NO20051159L (no) 2005-04-26

Family

ID=31715805

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051159A NO20051159L (no) 2002-08-07 2005-03-04 Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein

Country Status (10)

Country Link
EP (1) EP1575510A4 (ja)
JP (1) JP2006509726A (ja)
KR (1) KR20050053607A (ja)
CN (1) CN101123993A (ja)
AU (1) AU2003259073A1 (ja)
CA (1) CA2494908A1 (ja)
IL (1) IL166706A0 (ja)
NO (1) NO20051159L (ja)
NZ (1) NZ538145A (ja)
WO (1) WO2004014306A2 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007139120A1 (ja) * 2006-05-30 2009-10-08 国立大学法人大阪大学 アミロイドβクリアランス促進剤
KR100982909B1 (ko) * 2009-07-08 2010-09-20 고려대학교 산학협력단 아탁신-1 유전자 또는 아탁신-1 단백질을 유효성분으로 포함하는 항암용 조성물 및 그를 이용한 항암제 스크리닝 방법
WO2011015572A1 (en) * 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2019032613A1 (en) * 2017-08-08 2019-02-14 Ionis Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR MODULATING PROTEIN AGGREGATION
US20220411794A1 (en) 2019-10-23 2022-12-29 Universitaet Wien Rna oligonucleotides for preventing aggregation of proteins
WO2023205579A1 (en) * 2022-04-18 2023-10-26 The Regents Of The University Of California Compositions and methods for disrupting pathological aggregates

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001575A1 (en) * 1996-07-08 1998-01-15 Pioneer Hi-Bred International, Inc. Transformation of zygote, egg or sperm cells and recovery of transformed plants from isolated embryo sacs
EP1001987B1 (en) * 1997-08-01 2010-12-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
US7799535B1 (en) * 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
US20030060436A1 (en) * 1998-11-05 2003-03-27 Clifford Kent Weber Esq. Treatment of parkinson's disease with oligonucleotides
DE19925073C2 (de) * 1999-06-01 2001-07-19 Stefan Weiss Nucleinsäuremoleküle mit spezifischer Erkennung von nativem PrP·S··c·, Herstellung und Verwendung
US6420122B1 (en) * 1999-09-27 2002-07-16 Massachusetts Institute Of Technology Methods of screening for agents that inhibit aggregation of polypeptides
US20030027210A1 (en) * 2001-01-03 2003-02-06 Daniel Benjamin Alpha synuclein aggregation assays
EP1392849B2 (en) * 2001-02-15 2012-01-18 University Of Chicago Yeast screens for agents affecting protein folding
AU2002326589B2 (en) * 2001-08-07 2008-06-05 University Of Delaware Compositions and methods for the prevention and treatment of Huntington's disease
JPWO2003044197A1 (ja) * 2001-11-21 2005-03-24 独立行政法人科学技術振興機構 ハンチントン病遺伝子転写因子
US20030235823A1 (en) * 2002-06-24 2003-12-25 The University Of Alabama Nucleotide sequences that code for torsin genes, torsin proteins, and methods of using the same to treat protein-aggregation

Also Published As

Publication number Publication date
CN101123993A (zh) 2008-02-13
EP1575510A2 (en) 2005-09-21
NZ538145A (en) 2008-05-30
AU2003259073A1 (en) 2004-02-25
IL166706A0 (en) 2006-01-15
KR20050053607A (ko) 2005-06-08
WO2004014306A3 (en) 2006-05-18
JP2006509726A (ja) 2006-03-23
EP1575510A4 (en) 2007-12-26
WO2004014306A2 (en) 2004-02-19
CA2494908A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
NO20053855L (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
NO20055173L (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
NO20051159L (no) Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein
MEP20908A (en) Thienopyrazoles
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
NO20075508L (no) Stannsoporfinpreparater og administrering
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
ATE402147T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
WO2003066806A3 (en) Therapeutic use of aziridino compounds
ATE338560T1 (de) Pharmazeutische zusammentsetzung zur medizinischen behandlung von gutartiger prostathyperplasie, dessen vorbereitungsmethode und dessen therapeutische verwendung
BRPI0410305A (pt) composições de um inibidor seletivo de ciclooxigenase-2 á base de benzenossulfonamida ou metilsulfonilbenzeno e um agente colinérgico para o tratamento de redução de fluxo sangüìneo ou traumatismo do sistema nervoso central
UA92465C2 (ru) Терапевтические применения ингибиторов rtp801
DE60308127D1 (de) Pharmazeutische Zusammentsetzung zur medizinischen Behandlung von gutartiger prostathyperplasie, dessen Vorbereitungsmethode und dessen therapeutische Verwendung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application